Global Breast Cancer Drugs Market
INTRODUCTION
- To define global breast cancer drugs market.
- To analyze the existing drugs with respect to their competitive advantage and adverse effects
- To understand the ongoing clinical trails and provide pipeline analysis
- To understand and analyze the regulatory framework , clinical data related to drug efficacy and safety
- To identify and analyze the unmet needs and the emerging opportunities in the breast cancer drug market
- To identify and analyze comprehensively the market structure with respect to the factors influencing the market growth and industry specific challenges.
- To identify the major drivers and restraints of the market
- To analyze and forecast revenues of market segments with respect to geographies (North America, Europe, Asia & Rest of the World).
- To strategically profile and analyze market players and their core competencies in the field of breast cancer drugs for each of its market segment.
- To track and analyse recent developments, alliances, joint ventures, mergers & acquisitions that has an impact on breast cancer drugs market.
REPORT DESCRIPTION
There are about one million new cases of breast cancer every year. Breast cancer accounts for about 10% of world wide cancer. There has been significant increase in awareness levels with respect to impact on survival rates incase of early diagnosis. Therefore, opening novel opportunities for breast cancer drugs market. The market has several products for breast cancer treatment such as, hormonal therapies, chemotherapies, combinations and targeted therapies, etc. However, unmet needs with respect to severe adverse effects and unconvincing safety data associated with these treatments are therefore, enhancing opportunities for market expansion of novel drugs that focus on improved safety and efficacy. The above factors are demanding R&D focus among the pharmaceutical companies. Therefore, compelling the market participants to effectively understand the key market dynamics, competitive scenario, drug pipeline and market forecast, to have a holistic perspective of the breast cancer drugs market.
INFORMATION SOURCES
Each of the section will provide market data, market drivers, trends and opportunities, top-selling products, key players, and competitive outlook. This report will also provide market tables for various geographic regions covering sub segments and micro markets. In addition the report also provides about 40 company profiles. Key market developments will be sourced from the top companies that are profiled. Secondary research will progress through both paid and unpaid sources. We will conduct primary research to provide in-depth understanding of the market.
Exclusive indicates content/data unique to MarketsandMarkets and not available with any competitors.
1. Market Overview
1.1. Breast cancer – introduction (causes of cancer, types & therapies)
1.2. Breast cancer prevalence & incidence rates
1.3. Improving survival rates
1.4. Recent advancement in imaging technologies in cancer diagnostics
1.5. R&D focus of pharmaceutical companies
1.6. Increasing efforts to enhance awareness levels
1.7. Developed nations vs. developing nations (diagnosis to therapeutics)
1.8. Focus areas: conventional vs. novel drugs
1.9. Emerging avenues in cancer drugs market
2. Market Dynamics
2.1. Drivers
2.2. Restraints
2.3. Challenges
3. Market Estimates (2009 to 2014)
3.1. Sales (by Brand)
3.2. Market Size
4. Market Structure (Market Dynamics, Market Estimates, Strategic Analysis)
4.1. Chemotherapy Drugs
4.1.1. Anthracyclines
4.1.1.1. Adriamycin (doxorubicin)
4.1.1.2. Ellence (epirubicin)
4.1.2. Taxanes
4.1.2.1. Taxol (paclitaxel)
4.1.2.1.1. Abraxane IV ( Paclitaxel Protein Bound Injection)
4.1.2.2. Taxotere (docetaxel)
4.1.3. Antimetabolites
4.1.3.1. Adrucil (fluorouracil)
4.1.3.2. Xeloda (capecitabine):
4.1.3.3. Gemzar (gemcitabine)
4.1.4. Alkylating Agents - Cytoxan (cyclophosphamide)
4.1.5. Epothilones - Ixempra (Ixabepilone)
4.2. Hormone Therapy
4.2.1. SERMs (Selective Estrogen-Receptor Modulators)
4.2.1.1. Tamoxifen
4.2.1.2. Evista (raloxifene)
4.2.1.3. Fareston (toremifene)
4.2.2. Aromatase Inhibitors
4.2.2.1. Femara (letrozole)
4.2.2.2. Arimidex (anastrozole)
4.2.2.3. Megace (megestrol)
4.2.3. Other Hormonal Therapies
4.2.3.1. Zoladex (goserelin acetate)
4.2.3.2. Faslodex (fulvestrant)
4.2.3.3. Halotestin (Fluoxymesterone)
4.3. Targeted Therapy
4.3.1. Monoclonal Antibodies
4.3.1.1. Avastin (Bevacizumab)
4.3.1.2. Herceptin (Trastuzumab)
4.3.2. Tyrosine kinase inhibitor - Tykerb (Lapatinib)
5. Pipeline Analysis
5.1. Afinitor
5.2. BSI-201
5.3. NeuVax
5.4. Stimuvax
5.5. Custirsen Sodium (OGX-011)
5.6. Others
6. Competitive Landscape
6.1. Key strategies – An analysis
6.2. Market share
6.3. Recent developments
7. Geographic Analysis
7.1. North America
7.2. Europe
7.3. Asia
7.4. ROW
8. Patent Analysis
9. Company Profiles
9.1. Novartis AG
9.2. Pfizer
9.3. Oncogenex
9.4. Apthera Inc
9.5. Astellas
9.6. BioNumerik Pharmaceuticals
9.7. Oncothyreon Inc
9.8. Bipar Sciences
9.9. Others
Growth opportunities and latent adjacency in Global Breast Cancer